INDIANAPOLIS and
NASHVILLE, Tenn., June 17, 2015
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sarah Cannon
Research Institute (SCRI) today announced a strategic partnership
to co‑develop an investigational oncology compound, LY3023414, a
PI3K/mTOR dual inhibitor. Under the agreement, SCRI will
collaborate with Lilly to provide clinical development expertise
and program design, as well as medical oversight and trial
management. Patient enrollment for the initial Phase II clinical
trial is underway.
"Lilly has a long history of leading innovation in cancer
therapy with the goal to offer patients improved treatment
outcomes," said Christopher A. Slapak, M.D., vice
president, early phase clinical research for Lilly. "This strategic
partnership is an exciting step to foster further collaboration
with SCRI in advancing the field of cancer research."
The partnership supports the development of this novel targeted
cancer therapy, including flexible and efficient program design and
implementation, as well as more rapid patient enrollment to
clinical trials by accessing SCRI's large network of
patients.
"Our clinical trial management capabilities and scientific
leadership, combined with Lilly's leading drug development
expertise, furthers our mission to advance therapies for patients
seeking novel cancer medicines," said Dee
Anna Smith, CEO of SCRI. "Through partnerships like this
one, we can accelerate the time it takes to bring clinical trials
into communities for those fighting cancer."
About Sarah Cannon Research Institute
Sarah Cannon
Research Institute (SCRI) is the research arm of HCA's global
cancer enterprise, Sarah Cannon.
Focused on advancing therapies for patients, it is one of the
world's leading clinical research organizations conducting
community-based clinical trials in oncology, cardiology and
orthopedics through affiliations with a network of more than 1,000
physicians across the United
States and United Kingdom.
SCRI has led more than 170 first-in-man clinical trials since its
inception in 1993, and has been a clinical trial leader in nearly
80 percent of approved cancer therapies in the last 10 years.
Additionally, SCRI offers management, regulatory, and other
research support services for drug development and industry
sponsors as well as strategic investigator sites through its
contract research organization (CRO), SCRI Development Innovations.
For more information, visit sarahcannon.com.
About Lilly Oncology
For more than fifty years,
Lilly has been dedicated to delivering life-changing medicines and
support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making
life better for all those affected by cancer around the world. To
learn more about Lilly's commitment to people with cancer, please
visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high‑quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us
at www.lilly.com and newsroom.lilly.com/social-channels.
P-LLY
© Lilly USA, LLC 2015. ALL
RIGHTS RESERVED.
Lilly Forward-Looking Statement
This press release contains "forward-looking statements" (as
that term is defined in the United States Private
Securities Litigation Reform Act of 1995) regarding the partnership
between Lilly and SCRI. This press release reflects Lilly's
current beliefs. However, there are substantial risks and
uncertainties in the process of drug research, development, and
commercialization. Among other risks, there can be no guarantee
that this investigational molecule will receive regulatory
approval, or, if approved, that it will achieve intended benefits
or become a commercially successful product. For further discussion
of these and other risks and uncertainties that could cause actual
results to differ materially from Lilly's expectations, please see
the company's latest Forms 10-K and 10-Q filed with the U.S.
Securities and Exchange Commission. Except as required by law,
Lilly undertakes no duty to update forward-looking statements.
Refer to:
Karen Glowacki; kglowacki@lilly.com;
(317) 370-1177 (Lilly)
Gabrielle Hannafan;
gabrielle.hannafan@scresearch.net; (615) 524-4235 (Sarah Cannon)
Neil Hochman; n.hochman@togorun.com;
(212) 453-2067 (TogoRun)
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Logo - http://photos.prnewswire.com/prnh/20150616/223394LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eli-lilly-and-company-enters-into-strategic-partnership-with-sarah-cannon-research-institute-to-develop-investigational-oncology-therapy-300100203.html
SOURCE Eli Lilly and Company